Fair value rises to USD 4.55 for Lexicon Pharmaceuticals stock

Published on 10/05/2026 at 01:53 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Cantor set a USD 8.00 target for Lexicon Pharmaceuticals stock. Second-quarter revenue was USD 692,000 versus USD 3.99 million consensus.

LXRX, US5288723027, Illustration mit AI erstellt.

Fair value for Lexicon Pharmaceuticals (US5288723027) increased from USD 3.77 to USD 4.55 in an update published by Yahoo Finance on October 2, 2026. The revised view followed progress in the fully enrolled Phase 3 SONATA HCM trial, with data expected in the first quarter of 2027.

SONATA HCM sets the next milestone

Lexicon has exceeded the enrollment target of 500 patients across more than 130 sites in 20 countries, according to Investing.com on September 28, 2026. The trial is testing sotagliflozin in symptomatic hypertrophic cardiomyopathy, giving the development program a defined clinical milestone rather than an open-ended research timeline.

The same report said Lexicon plans to resubmit its ZYNQUISTA application for type 1 diabetes in the fourth quarter of 2026. That regulatory date and the first-quarter 2027 SONATA HCM readout create two separate development checkpoints for the company.

Results show a sharp revenue gap

Lexicon reported second-quarter 2026 revenue of USD 692,000, compared with USD 3.99 million expected by analysts, according to MarketBeat on September 28, 2026. The company also posted a USD 0.06 loss per share against a USD 0.05 consensus loss, a USD 0.01 wider loss than expected.

MarketBeat reported a five-analyst average rating of Hold, with three Buy ratings, one Hold rating and one Sell rating. Cantor Fitzgerald initiated coverage with an Overweight rating and a USD 8.00 target, while the average 12-month target stood at USD 5.70.

Nasdaq valuation stays below analyst targets

Lexicon was last at USD 1.82 on Nasdaq on October 2, 2026 at 4:00 p.m. ET, with a market capitalization of USD 808.4 million. The 52-week range was USD 1.10 to USD 2.68, placing the last quote USD 0.86 below the yearly high.

Lexicon Pharmaceuticals is a biotechnology company developing small-molecule medicines, including sotagliflozin and LX9211. The next reported date listed for the company is November 11, 2026, with consensus estimates of a USD 0.06 loss per share and USD 2.83 million in revenue, according to Makkler.